Lyra Therapeutics (LYRA) Return on Invested Capital (2023 - 2025)

Quarterly Return on Invested Capital rose 10.0% to 0.04% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.04% through Dec 2025, up 10.0% year-over-year, with the annual reading at 0.71% for FY2025, 69.0% down from the prior year.

Lyra Therapeutics' Return on Invested Capital history spans 3 years, with the latest figure at 0.04% for Q4 2025.

  • Return on Invested Capital came in at 0.04% for Q4 2025, down from 0.26% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.26% in Q3 2025 to a low of 0.15% in Q2 2025.
  • The 3-year median for Return on Invested Capital is 0.02% (2024), against an average of 0.01%.
  • The largest YoY upside for Return on Invested Capital was 30bps in 2025 against a maximum downside of -13bps in 2025.
  • Lyra Therapeutics' Return on Invested Capital stood at 0.01% in 2023, then plummeted by -673bps to 0.06% in 2024, then surged by 169bps to 0.04% in 2025.
  • Per Business Quant, the three most recent readings for LYRA's Return on Invested Capital are 0.04% (Q4 2025), 0.26% (Q3 2025), and 0.15% (Q2 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROIC (Qtr)
1 Quantum Biopharma 1,384,976.65 Bn 1,384,976.64 Bn - -
2 Alterity Therapeutics 777,208.84 Bn 777,208.81 Bn - -
3 Legend Biotech 2,801.00 Bn 2,800.10 Bn 242.10 Mn -
4 Nanobiotix 2,226.01 Bn 2,225.95 Bn - -
5 Akari Therapeutics 605.66 Bn 605.66 Bn - -0.01%
6 Vertex Pharmaceuticals 110.17 Bn 102.92 Bn 2.59 Bn 0.00%
7 Regeneron Pharmaceuticals 66.86 Bn 58.11 Bn 3.31 Bn 0.00%
8 Evaxion A 65.12 Bn 65.10 Bn - -0.01%
9 Alnylam Pharmaceuticals 39.94 Bn 36.94 Bn 959.66 Mn 0.01%
10 Lyra Therapeutics - - - 0.04%

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 0.04%
Sep 30, 2025 0.26%
Jun 30, 2025 -0.15%
Mar 31, 2025 -0.11%
Dec 31, 2024 -0.06%
Sep 30, 2024 -0.04%
Jun 30, 2024 -0.02%
Mar 31, 2024 -0.01%
Dec 31, 2023 -0.01%